GFAP and Down syndrome: For plasma GFAP (Figs. 1b, 2b), there were main effects of both amyloid PET status (F = 21.307, p < 0.001) and syndrome diagnosis (F = 3.072, p = 0.048); thus, both brain amyloidosis and disease severity independently contribute to the increase in plasma GFAP level.